Thank you for submitting your manuscript for consideration by The EMBO Journal. It has now been seen by three reviewers, whose comments are attached below. Two of these reviewers are supportive of publication pending only minor modification. However, referee 2 retains major reservations, detailing that although the work is of high technical quality, too little new functional insight is gained from the analysis.
While I have to agree to some extent with this criticism regarding new functional information, I also do not want to ignore the more positive (even if in one case not very detailed) recommendations of the other two referees. Furthermore, I also note that referee 2 has provided some specific suggestions on how the functional implications could be strengthened. I therefore feel we should be able to consider a revised version of the manuscript for publication if you should be able to obtain some further functional data along the lines suggested by referee 2. In addition, it will also be important to solidify the final model and/or speculations, as requested by both referee 1 and 2.
Please be reminded that it is EMBO Journal policy to allow a single round of major revision only, and that it is therefore essential that you diligently answer to all the points raised at this stage if you wish the manuscript ultimately to be accepted. In any case, please do not hesitate to get back to us should you need feedback on any issue regarding your revision.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal REFEREE REPORTS:
Referee #1 (Remarks to the Author):
The manuscript by Isabet et al reports on the crystal structure of GTP-bound Arf6 with the second leucine zipper from the JNK-interacting protein JIP4, a scaffold protein that can bind to either microtubule motor protein kinesin or dynein. In the structure two Arf6 molecules interact on either side of a dimer of the leucine zippers. Analytical ultracentrifugation confirms that such a complex can form in solution or, if Arf6 is more limiting, a complex of one Arf6 and the leucine zipper dimer can also form, a complex more likely to be formed in vivo when Arf6 is anchored to the membrane. This interaction is specific to Arf6 and not shared by other Arf proteins. The sites of interaction between Arf6 and JIP4 reveal the basis for this selectivity which resides in three residues in the interswitch region (T,K,N) and a threonine at the c-terminal end of switch II, not found in Arf1. To confirm the importance of these sites of interaction the four residues in Arf1 were replaced with those in Arf6 and this mutated Arf1 was now found by surface plasmon resonance to bind to the leucine zipper of JIP4 with high affinity. In Fig. 7 the authors dock Arf6 on the PM and due to steric hindrance factors propose that it is one Arf6 that interacts with the dimer of JIP4 at the PM which would promote binding to dynein-dynactin and not kinesin. As is often the case from the Mentrey group, this study is most compelling, thought-provoking and clearly described. It highlights yet again that specific Arf-effector interactions can occur outside the switch regions and predicts that there will be other isoform-specific Arf interactions to come.
I have only one small request in the way of a modification to Fig. 7 . First, in C the relationship between the JIP dimer bound to Arf6-GTP with kinesin and dynein is not clear from the arrows. Dynein-dynactin binding to the complex is favored whereas kinesin binding is not -this should be shown more clearly -at present it seems to indicate the opposite. Also, perhaps the docked Arf6 on the membrane could be depicted more clearly so the orientation can be seen. Is it clear exactly in what position myristoylated Arf6 would be oriented at the membrane?
Referee #2 (Remarks to the Author):
The authors reported the crystal structure of ARF6-GTP bound to the LZII motif of JIP4, a specific effector of ARF6. The structure shows that ARF6-GTP binds to LZII to form a heterotetramer arranged in an ARF6-(LZII)2-ARF6 configuration, which is further confirmed by analytical ultracentrifugation. Structural data combined with mutagenesis reveals the structural basis of JIP3/4's specificity towards ARF6, and explain how JIP3/4 distinguishes between two ARF proteins from the same subfamily. Overall, the results are interesting and sound but not significant enough to merit publication in EMBO J due to inadequate functional insights derived from the structure.
Major points:
(1)
The structural and mutational data are merely confirmation of authors' previous finding that JIP4 is the specific effector of ARF6. Given that the authors have demonstrated that ARF6, through its binding to JIP3/4, regulates the interaction of JIP proteins with the motor proteins involved in cytokinesis, it is expected that the authors could demonstrate the importance of the ARF6-JIP4 interaction in a context related to their cellular functions, e.g. the effects of disruption of the ARF6-JIP4 interaction on the interaction of JIP3/4 with kinesin-1. (2) The model of the ARF6-JIP3/JIP4 complex with membranes is purely speculative and therefore any conclusion drawn from the model should be downplayed. The presence of the heterotrimer of ARF6-(JIP4)2 in solution does not necessarily indicates that a dimer of JIP4 interacts with only one of ARF6-GTP on the membrane.
Minor points:
It would be more informative to show the schematic diagram of JIP4 with the LZII motif highlighted.
(2) Figure 3 , the peak corresponding to free (JIP4)2 in the analysis of ARF6-(JIP)2 (black line) shows large deviation with the position of free (JIP4)2 (red line). Any explanation for this difference ? (3)
Fig4C. The figure is too crowded and should be shown in stereo diagrams.
Referee #3 (Remarks to the Author):
Isabet et al. determine the structure of Arf6-GTP in complex with JNK interacting protein 4 and the basis for Arf6 specificity and also use modeling to determine the form and orientation of the Arf6-GTP-JIP4 complex at a membrane. They found that the edges of the switch regions of Arf6 interact with JIP4, providing specificity and distinguishing the interaction from Rab -effector interactions in which specificity is determined outside the switch region. Based on modeling, a 1:2 complex of Arf6:JIP4 associates with membranes. The biological significance is discussed. The experiments are into the molecular basis of Arf action. Please find enclosed the revised version of our manuscript entitled 'The structural basis of Arf effector specificity: the crystal structure of GTP-bound ARF6 in a complex with the JNK-interacting protein JIP4' by Isabet et al. that we propose for publication in EMBO Journal. We would like to thank you for offering us the opportunity to respond to the referees' criticisms and to resubmit a revised version.
We wish to express our thanks to the reviewers for their comments. We are happy that all three found our study interesting and that two of them were recommending publication with little modifications. We believed we addressed all their queries and criticisms and revised the manuscript accordingly. Our specific responses to the reviewers' comments are detailed in the accompanying rebuttal letter.
The main point of the present manuscript is to provide for the first time the structural basis for specific effector recognition among the Arfs subfamily, a long standing question in the ARF andmore generally small GTPases -field. Concerning the addition of new functional informations and as detailed in our response to Point 1 of Referee 2, the functional consequence of interfering with ARF6 binding to JIP3/4 in a context related to their cellular functions has already been reported in our previous publication (Montagnac et al, 2009) ; these data are now clearly mentioned in our revised manuscript.
Referee #1 (Remarks to the Author): Fig.7C 
the relationship between the JIP dimer bound to Arf6-GTP with kinesin and dynein is not clear from the arrows. Dynein-dynactin binding to the complex is favored whereas kinesin binding is not -this should be shown more clearly -at present it seems to indicate the opposite.
In order to be clearer and prevent confusion, we removed the arrows and motor names (Fig.7C) .
2a) Also, perhaps the docked Arf6 on the membrane could be depicted more clearly so the orientation can be seen...
We have modified Fig.7 in order to better depict ARF6 orientation at the membrane (switch II in red, interswicth in green, nucleotide in sphere representation, the myristoylated amphipatic Nterminus helix is shown with a blue cylinder indicating the N-terminal part of the molecule).
2b) Is it clear exactly in what position myristoylated Arf6 would be oriented at the membrane?
The position of the myristoylated ARF1 and ARF6 at the membrane can be precisely oriented. As mentioned in the manuscript, the interaction of ARF1/ARF6 with the membrane is mainly mediated by the myristoylated N-terminal helix. The hydrophobic face of the amphipatic N-terminal helix of ARF1/ARF6 lies on the membrane with several hydrophobic residues inserted into the membrane bilayer (Antonny et al., Biochemistry, 1997) . This interaction allows the myristate, which is covalently attached at the Gly2 position, to insert into the membrane and strengthen the interaction with membrane. Also, electrostatic interactions have been detected between phospholipids and ARF1 presumably due to a basic patch formed on the protein surface by residues mainly on the Nterminus part (Paris et al., JBC, 1997) . Altogether, the myristate, the amphipatic helix and the basic patch, all located at the N-terminal part of the protein, force ARF1/ARF6 to be close to the membrane and to orientate in a constraint manner. In Fig.7A , our modelling of the ARF6-JIP4 complex according to the orientation of membrane-bound ARF6 has to accommodate not only one ARF6 molecule orientation, but a second ARF6 molecule orientation which would further constraint the orientation of the complex with JIP4 standing perpendicular to the membrane. In Fig.7B , we modelled the heterotetrameric complex with JIP4 lying tangentially to the membrane showing that only one ARF6 molecule would be oriented with its N-terminal helix facing the membrane, while the second ARF6 molecule could not bind the membrane since its N-terminal part would be facing the cytosol opposite to the membrane. The option we would favour is represented in Fig. 7C , where only one membrane-anchored ARF6 molecule interacts with JIP4 tangential to the membrane. In order to clarify this point, a more detailed explanation is given in the legend of Fig.7 .
(1) "The structural and mutational data are merely confirmation of authors' previous finding that JIP4 is the specific effector of ARF6. Given that the authors have demonstrated that ARF6, through its binding to JIP3/4, regulates the interaction of JIP proteins with the motor proteins involved in cytokinesis, it is expected that the authors could demonstrate the importance of the ARF6-JIP4 interaction in a context related to their cellular functions, e.g. the effects of disruption of the ARF6-JIP4 interaction on the interaction of JIP3/4 with kinesin-1. "
The importance of the ARF6-JIP4 interaction in the context of its cellular function was addressed by Montagnac et al. (Current Biology, 2009) . In this study, we reported a mutant ARF6 protein obtained by swapping the interswitch region between ARF6 and ARF1 (ARF6 iSW ) that prevented interaction with JIP4 (as shown by pull-down assay), without affecting interaction with FIP3 or ARHGAP21, two known ARF6 effectors. Of note, the crystal structure of the ARF6-JIP4 complex in the present report rationalizes why interswitch swapping prevents the interaction of JIP4 with ARF6 iSW . When overexpressed in HeLa cells, ARF6 iSW led to a 3-fold increase of cells at cytokinesis and correlated with a reduction of endosomes accumulating in the intercellular bridge, indicating that ARF6 function in cytokinesis required its interaction with JIP. These issues are now discussed in the revision version of the manuscript. Analyzing the consequence of disrupting the ARF6-JIP4 interaction on the association of JIP3/4 with kinesin-1 would be interesting, however we believe this is far beyond the scope of the present manuscript. We previously demonstrated (Montagnac et al., Current Biology, 2009 ) that binding of ARF6 and kinesin-1 (KLC1) to JIP4 is antagonistic, indicating that most likely ARF6-and KLC1-binding sites on JIP4 are overlapping. Thus, disruption of ARF6-JIP4 interaction would probably also disrupt KLC1-binding to JIP4 making in vivo experiments very difficult to interpret. Rather, we believe that solving the crystal structure of the JIP4:KLC1 complex would be a prerequisite to the experiments suggested by the reviewer. We are actively working in this direction. But, at this stage, we believe this is beyond the scope of the present study. Our model of the ARF6-JIP4 complex at the membrane is based on experimental data and modelling. First, our crystal structure shows how ARF6 interacts with JIP4 that was confirmed in solution using site-directed mutagenesis and binding assays. Second, and as detailed in Point 2b of Referee 1, the orientation of ARF6 with respect to the membrane can be accurately predicted and modelled. However, in order to comply with the referee's request and prevent any confusion with the fact that this is a model, we brought some corrections in the discussion part of the manuscript.
(2b) "The presence of the heterotrimer of ARF6-(JIP4)2 in solution does not necessarily indicates that a dimer of JIP4 interacts with only one of ARF6-GTP on the membrane. "
We agree that the existence of an ARF6-JIP4 heterotrimer in solution does not necessarily indicates that a dimer of JIP4 interacts with only one ARF6 molecule on membrane. In order to prevent any confusion, we removed this note in the result part "A model for the interaction of the JIP4-ARF6 complex at the membrane interface" in the manuscript.
Minor points:
(1) It would be more informative to show the schematic diagram of JIP4 with the LZII motif highlighted.
We modified Fig. 2 by adding a schema of the full-length JIP4 protein with its LZII domain indicated (now Fig.2A ). The alignment of the JIP3 and JIP4 LZII domains and the structure of the LZII domain are now shown in Fig.2B and Fig2C, respectively. The figure legend and the text have been modified accordingly. In fact, there is no deviation between the center of the free (JIP4)2 peak whether it is alone or in the presence of ARF6 (1.5S in each case). The only difference is that the free (JIP4)2 peak determined in the c(S) sedimentation coefficient distribution appears broader when analyzing the ARF6-(JIP)2 mixture than free (JIP4)2 alone. This is only due to a higher fitting uncertainty when several species are present in a sample. However we understand that this apparent peak broadening may have raised questions. We have therefore refined the quality of data analysis by significantly increasing the resolution of the c(S) distribution determination. This leads to a better definition and narrowing of each peak. We have therefore modified figure 3, which now shows better that the position of the free (JIP4)2 peak remains constant. 
